On Tuesday, BeiGene (ONC.US) surged over 9% to $334.20. According to financial results, BeiGene achieved total operating revenue of 17.518 billion yuan in the first half of 2025, representing a 46.03% year-over-year increase, with product revenue reaching 17.36 billion yuan, up 45.8% year-over-year. The company recorded a net profit of 450 million yuan, marking BeiGene's first turnaround to profitability this year.

The growth in product revenue for the first half of 2025 was driven by increased sales of the company's proprietary products Brukinsa® (zanubrutinib) and Tevimbra® (tislelizumab), as well as higher sales of Amgen-licensed products. Among these, the core proprietary product zanubrutinib delivered outstanding performance, maintaining its leading position in both the US and global BTK inhibitor markets.

In the first half of 2025, zanubrutinib achieved global sales of 12.527 billion yuan, representing a 56.2% year-over-year increase. In the US market, the product generated sales of 8.958 billion yuan, up 51.7% year-over-year. With its best-in-class clinical profile, zanubrutinib has been rapidly adopted by patients and physicians across the United States. Zanubrutinib stands as both the largest market share product and the fastest-growing branded product in the US market.